Subscribe to one of our feedsfont size
PrintBlog: Finance
FINANCE:
Biotech Gets A FlatThe life sciences sectors fails to muster a single IPO in the second quarter.
The IPO window – a notion that had been fading within the biotech arena – appears to be back and it’s closed. While there have been some drivers within the sector to weaken Wall Street’s appetite for biotech IPOs – such as the aftermarket performance of deals in recent years, risk-averse investors, and a cautious FDA – the housing meltdown, skyrocketing oil prices and the credit crunch are taking their toll in the IPO world well beyond the life sciences.
- Obama’s Pick of Daschle May Test Conflict-of-Interest Pledge
The New York Times - Personal medicine is goal of Eli Lilly & Co.
The Arizona Republic - Health Insurers Offer to Accept All Applicants, on Condition
The New York Times - Amgen, Takeda's Cancer Drug Test Stopped After Deaths
Bloomberg - Fast-food ad ban could cut child obesity: U.S. study
Reuters - Federal Court Upholds Drug Privacy Law
The New York Times - Use of Antipsychotics in Children Is Criticized
The New York Times - Doctors transplant windpipe with stem cells
Associated Press - FDA Sending Inspectors to Other Nations
The Washington Post - Stem cells restore hearing, vision in animals
Reuters